Omentec Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Omentec was formed around omentin, a protein selectively expressed in visceral (central) adipose tissue, where fat is stored. Visceral obesity, as opposed to subcutaneous (peripheral) fat accumulation, is associated with a higher risk of diabetes and cardiovascular disease. That omentin is found mostly in visceral adipose tissue suggests it may be an important signaling factor in fat metabolism, insulin sensitivity, and inflammation, with therapeutic and diagnostic applications.
You may also be interested in...
Marrying Glucagon with GLP-1 to Treat Obesity
Because glucagon raises blood glucose in the liver, it's counter-intuitive to think of it as the basis for a strategy to treat obesity and its associated consequences, including adult onset diabetes. But a research team has shown that a single-molecule "co-agonist" of glucagon and GLP-1 normalizes glucose tolerance and reduces body fat and weight in preclinical models. This molecular-level polypharmacy is particularly appealing in metabolic disease, where single mechanisms tend to offer only modest therapeutic effects.
Mining the Mitochondria for Clues to Cell Survival Mechanisms
Researchers have identified a protein in the mitochondria -- where cells generate the energy needed to drive biological processes -- that is dramatically upregulated by nutrient restriction. It appears to protect the cell from stress, in keeping with observations that caloric restriction diets slow aging. The researchers go on to show that a set of other proteins activated in turn by this process may be targets for the development of therapies for neurodegenerative diseases and diabetes.
Start-Ups in Obesity
The unanimous rejection of Sanofi-Aventis' obesity drug rimonabant by an FDA Advisory Committee in June hasn't put off the host of firms, large and small, seeking an answer to the obesity epidemic. Despite the many drug casualties in this area, still, it seems, no approach is ruled out.